Guizhou Yibai Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Guizhou Yibai Pharmaceutical Co Ltd (600594.CG)

Q3 202614 Jul – 21 Aug 2026

▼3▲1

Yibai's losses widen as main products slump and regulators fine it again

First-half loss balloons on 30% revenue drop Yibai's main products sold far less, cutting revenue about 30% and pushing the first-half net loss to roughly 80 million yuan, much wider than last year's 20 million yuan loss. Even after cutting costs 26%, spending still exceeded sales, so the core business is shrinking and losing money.
The widening loss and falling sales are the central force dragging the stock down.
Regulator fines 700,000 yuan over cough syrup quality Guizhou's drug regulator fined Yibai 700,000 yuan for failing manufacturing quality standards on children's cough syrup, including skipped ingredient tests and missing records. The company says this follows its earlier 2025 suspension and no new violations occurred, but it adds to a record of repeated quality problems.
The fine is a fresh regulatory penalty that reinforces quality and compliance risk.
Two-and-a-half years of losses top 700 million yuan With 2024, 2025 and first-half 2026 all negative, cumulative losses now exceed 700 million yuan. Research spending has fallen five years straight, from 136 million yuan in 2021 to 84 million in 2025, raising doubts about the pipeline needed to replace weak products.
It shows the losses are a long-running pattern, not a one-off, and future growth spending is being cut.
Buyback shares to be cancelled, lifting per-share value Yibai disclosed it will change the purpose of its share buyback to cancellation and reduce registered capital. Cancelling bought-back shares shrinks the number of shares outstanding, which can modestly raise earnings per share and signals some shareholder-friendly intent, though it does not fix the weak business.
It is the one clearly supportive capital action in the period, offering a small counterweight to the losses.

August 202614 Jul – 21 Aug 2026

▼3▲1

Yibai's losses widen as main products slump and regulators fine it again

First-half loss balloons on 30% revenue drop Yibai's main products sold far less, cutting revenue about 30% and pushing the first-half net loss to roughly 80 million yuan, much wider than last year's 20 million yuan loss. Even after cutting costs 26%, spending still exceeded sales, so the core business is shrinking and losing money.
The widening loss and falling sales are the central force dragging the stock down.
Regulator fines 700,000 yuan over cough syrup quality Guizhou's drug regulator fined Yibai 700,000 yuan for failing manufacturing quality standards on children's cough syrup, including skipped ingredient tests and missing records. The company says this follows its earlier 2025 suspension and no new violations occurred, but it adds to a record of repeated quality problems.
The fine is a fresh regulatory penalty that reinforces quality and compliance risk.
Two-and-a-half years of losses top 700 million yuan With 2024, 2025 and first-half 2026 all negative, cumulative losses now exceed 700 million yuan. Research spending has fallen five years straight, from 136 million yuan in 2021 to 84 million in 2025, raising doubts about the pipeline needed to replace weak products.
It shows the losses are a long-running pattern, not a one-off, and future growth spending is being cut.
Buyback shares to be cancelled, lifting per-share value Yibai disclosed it will change the purpose of its share buyback to cancellation and reduce registered capital. Cancelling bought-back shares shrinks the number of shares outstanding, which can modestly raise earnings per share and signals some shareholder-friendly intent, though it does not fix the weak business.
It is the one clearly supportive capital action in the period, offering a small counterweight to the losses.

Latest14 Jul – 21 Aug 2026

▼3▲1

Yibai's losses widen as main products slump and regulators fine it again

First-half loss balloons on 30% revenue drop Yibai's main products sold far less, cutting revenue about 30% and pushing the first-half net loss to roughly 80 million yuan, much wider than last year's 20 million yuan loss. Even after cutting costs 26%, spending still exceeded sales, so the core business is shrinking and losing money.
The widening loss and falling sales are the central force dragging the stock down.
Regulator fines 700,000 yuan over cough syrup quality Guizhou's drug regulator fined Yibai 700,000 yuan for failing manufacturing quality standards on children's cough syrup, including skipped ingredient tests and missing records. The company says this follows its earlier 2025 suspension and no new violations occurred, but it adds to a record of repeated quality problems.
The fine is a fresh regulatory penalty that reinforces quality and compliance risk.
Two-and-a-half years of losses top 700 million yuan With 2024, 2025 and first-half 2026 all negative, cumulative losses now exceed 700 million yuan. Research spending has fallen five years straight, from 136 million yuan in 2021 to 84 million in 2025, raising doubts about the pipeline needed to replace weak products.
It shows the losses are a long-running pattern, not a one-off, and future growth spending is being cut.
Buyback shares to be cancelled, lifting per-share value Yibai disclosed it will change the purpose of its share buyback to cancellation and reduce registered capital. Cancelling bought-back shares shrinks the number of shares outstanding, which can modestly raise earnings per share and signals some shareholder-friendly intent, though it does not fix the weak business.
It is the one clearly supportive capital action in the period, offering a small counterweight to the losses.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.